These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6193076)

  • 1. Conformational study of the neurotensin and substance P fragments: Pro-Arg-Arg-Pro and Arg-Pro-Lys-Pro.
    Cotrait M
    Int J Pept Protein Res; 1983 Jul; 22(1):110-8. PubMed ID: 6193076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line.
    Bidard JN; de Nadai F; Rovere C; Moinier D; Laur J; Martinez J; Cuber JC; Kitabgi P
    Biochem J; 1993 Apr; 291 ( Pt 1)(Pt 1):225-33. PubMed ID: 8471039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tachykinins (substance P, neurokinin A and neuropeptide gamma) and neurotensin from the intestine of the Burmese python, Python molurus.
    Conlon JM; Adrian TE; Secor SM
    Peptides; 1997; 18(10):1505-10. PubMed ID: 9437709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of Positively Charged Oligopeptides with Blood Plasma Proteins.
    Kotynia A; Marciniak A; Kamysz W; Neubauer D; Krzyżak E
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and binding of specifically mutated neurotensin fragments on a silver substrate: vibrational studies.
    Podstawka-Proniewicz E; Kudelski A; Kim Y; Proniewicz LM
    J Phys Chem B; 2011 Jun; 115(21):7097-108. PubMed ID: 21548565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on peptides. LXXXI. Application of a new arginine derivative, NG-mesitylene-2-sulfonylarginine, to the synthesis of substance P and neurotensin.
    Yajima H; Akaji K; Mitani K; Fujii N; Funakoshi S; Adachi H; Oishi M; Akazawa Y
    Int J Pept Protein Res; 1979 Aug; 14(2):169-76. PubMed ID: 489255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One- and two-dimensional 1H NMR study of the substance P fragment ARG-PRO-Lys-Pro.
    Otter A; Kotovych G; Stewart JM
    J Biomol Struct Dyn; 1986 Jun; 3(6):1121-31. PubMed ID: 2482748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt and (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu administered intravenously to beagle dogs.
    Tokumura T; Machida R; Tsuchiya Y; Sasaki A; Abe K; Tanaka T; Saeki Y
    J Pharm Sci; 1993 Jul; 82(7):725-8. PubMed ID: 8360847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformations of neurotensin in solution and in membrane environments studied by 2-D NMR spectroscopy.
    Xu GY; Deber CM
    Int J Pept Protein Res; 1991 Jun; 37(6):528-35. PubMed ID: 1917311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate specificity of aminopeptidase Ey from hen's (Gallus domesticus) egg yolk.
    Tanaka T; Ichishima E
    Comp Biochem Physiol B; 1993 May; 105(1):105-10. PubMed ID: 7684960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico molecular engineering for a targeted replacement in a tumor-homing peptide.
    Zanuy D; Flores-Ortega A; Jiménez AI; Calaza MI; Cativiela C; Nussinov R; Ruoslahti E; Alemán C
    J Phys Chem B; 2009 Jun; 113(22):7879-89. PubMed ID: 19432404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.
    Sefler AM; He JX; Sawyer TK; Holub KE; Omecinsky DO; Reily MD; Thanabal V; Akunne HC; Cody WL
    J Med Chem; 1995 Jan; 38(2):249-57. PubMed ID: 7830267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prosomatostatin processing in Neuro2A cells. Role of beta-turn structure in the vicinity of the Arg-Lys cleavage site.
    Brakch N; Boileau G; Simonetti M; Nault C; Joseph-Bravo P; Rholam M; Cohen P
    Eur J Biochem; 1993 Aug; 216(1):39-47. PubMed ID: 8103453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues.
    Heyl DL; Sefler AM; He JX; Sawyer TK; Wustrow DJ; Akunne HC; Davis MD; Pugsley TA; Heffner TG; Corbin AE
    Int J Pept Protein Res; 1994 Sep; 44(3):233-8. PubMed ID: 7822099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous high yield expression and purification of neurotensin and its functional fragment in Escherichia coli.
    Tapaneeyakorn S; Ross S; Attrill H; Watts A
    Protein Expr Purif; 2010 Nov; 74(1):65-8. PubMed ID: 20600945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta VI turns in peptides and proteins: a model peptide mimicry.
    Müller G; Gurrath M; Kurz M; Kessler H
    Proteins; 1993 Mar; 15(3):235-51. PubMed ID: 8456095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid sequence restriction in relation to proteolysis.
    Jörnvall H; Persson B
    Biosci Rep; 1983 Mar; 3(3):225-32. PubMed ID: 6407541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases.
    Kitabgi P
    Peptides; 2006 Oct; 27(10):2508-14. PubMed ID: 16904237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A conformational study of Lys-Arg-Asp-Ser and analogs, a series of potent antithrombotic peptides. An approach based on simulated annealing and 1H NMR.
    Meddeb S; Demaret JP; Ballini JP; Fiat AM; Jollès P; Ptak M; Vigny P
    J Biomol Struct Dyn; 1994 Apr; 11(5):959-81. PubMed ID: 7946066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation, structure and biologic activity of chicken intestinal neurotensin.
    Carraway R; Bhatnagar YM
    Peptides; 1980; 1(2):167-74. PubMed ID: 7243616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.